FILINGS
| AZNCF 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-11-03 | 6-K | RESULT OF GENERAL MEETING | View Document |
| 2025-11-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-11-03 | 6-K | FORM 6-K | View Document |
| 2025-10-28 | 6-K | DIRECTOR DECLARATION | View Document |
| 2025-10-28 | 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | View Document |
| 2025-10-22 | 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | View Document |
| 2025-10-20 | 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | View Document |
| 2025-10-20 | 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | View Document |
| 2025-10-14 | 6-K | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | View Document |
| 2025-10-07 | 6-K | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | View Document |
| 2025-10-06 | 6-K | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | View Document |
| 2025-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-09-29 | 6-K | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | View Document |
| 2025-09-29 | 6-K | AZN HARMONISES LISTING STRUCTURE | View Document |
| 2025-09-29 | 6-K | 6-K | View Document |
| 2025-09-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-09-22 | 6-K | KOSELUGO RECOMMENDED FOR EU APPROVAL | View Document |
| 2025-09-22 | 6-K | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | View Document |
| 2025-09-17 | 6-K | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | View Document |
| 2025-09-17 | 6-K | UPDATE ON RESOLUTE PHASE III TRIAL | View Document |
| 2025-09-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-08-28 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-26 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-21 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-08-15 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-12 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-07-29 | 6-K | FORM 6-K | View Document |
| 2025-07-24 | 6-K | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | View Document |
| 2025-07-22 | 6-K | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | View Document |
| 2025-07-16 | 6-K | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | View Document |
| 2025-07-14 | 6-K | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | View Document |
| 2025-07-07 | 6-K | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | View Document |
| 2025-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-06-26 | 11-K | FORM 11-K | View Document |
| 2025-06-24 | 6-K | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | View Document |
| 2025-06-13 | 6-K | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | View Document |
| 2025-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-06 | 6-K | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | View Document |
| 2025-06-02 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-06-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-05-27 | 6-K | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | View Document |
| 2025-05-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-21 | 6-K | DIRECTOR DECLARATION | View Document |
| 2025-05-20 | 6-K | ACQUISITION OF ESOBIOTEC COMPLETED | View Document |
| 2025-05-09 | 6-K | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | View Document |
| 2025-05-07 | 6-K | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | View Document |
| 2025-05-06 | 6-K | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | View Document |
| 2025-05-02 | 6-K | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | View Document |
| 2025-05-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-04-29 | 6-K | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | View Document |
| 2025-04-29 | 6-K | UPDATE ON CAPITELLO-280 PHASE III TRIAL | View Document |
| 2025-04-29 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2025-04-23 | SCHEDULE 13G/A | View Document | |
| 2025-04-22 | 6-K | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | View Document |
| 2025-04-11 | 6-K | RESULT OF AGM | View Document |
| 2025-04-10 | SCHEDULE 13G/A | View Document | |
| 2025-04-04 | 6-K | IMFINZI APPROVED IN EU FOR AEGEAN | View Document |
| 2025-04-04 | 6-K | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | View Document |
| 2025-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-31 | 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | View Document |
| 2025-03-31 | 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | View Document |
| 2025-03-21 | 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | View Document |
| 2025-03-17 | 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2025-03-17 | 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | View Document |
| 2025-03-17 | 6-K | ASTRAZENECA TO ACQUIRE ESOBIOTEC | View Document |
| 2025-03-12 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-03-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-07 | 6-K | NOTICE OF AGM | View Document |
| 2025-03-07 | 6-K | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | View Document |
| 2025-03-07 | 6-K | FORM 6-K | View Document |
| 2025-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | View Document |
| 2025-02-28 | 6-K | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | View Document |
| 2025-02-26 | 6-K | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | View Document |
| 2025-02-19 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
| 2025-02-18 | IRANNOTICE | IRANNOTICE | View Document |
| 2025-02-18 | 20-F | FORM 20-F | View Document |
| 2025-02-18 | 6-K | FORM 6-K | View Document |
| 2025-02-18 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-02-18 | 6-K | ANNUAL FINANCIAL REPORT | View Document |
| 2025-02-18 | 6-K | DIRECTORATE CHANGE | View Document |
| 2025-02-06 | 6-K | FINAL RESULTS | View Document |
| 2025-02-05 | EFFECT | View Document | |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-02-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | View Document |
| 2025-01-28 | 6-K | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | View Document |
| 2025-01-24 | SCHEDULE 13D/A | View Document | |
| 2025-01-21 | F-6 | View Document | |
| 2025-01-21 | 6-K | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | View Document |
| 2025-01-17 | 6-K | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | View Document |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-12-26 | 6-K | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | View Document |
| 2024-12-23 | 6-K | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | View Document |
| 2024-12-16 | 6-K | DIRECTORATE CHANGE | View Document |
| 2024-12-05 | 6-K | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
